A
Actithera
Radioligand therapies for targeted cancer treatment, utilizing a proprietary chemistry platform for prolonged tumor retention and preservation of healthy tissue
About Actithera
Founded by Andreas Goutopoulos in 2021, Actithera is a radiopharmaceutical biotech company that translates medicinal chemistry insights into next-generation radioligand therapies.
The company was born from a deep expertise in small molecule oral drug design and a bold vision to revolutionize cancer treatment. Goutopoulos’ background in the field has been pivotal in shaping the company’s direction.
Actithera has a unique medicinal chemistry approach for the design of radiotherapeutics with prolonged tumor retention, while sparing healthy tissues. The company links radioactive isotopes to carefully designed molecules, ensuring rapid, specific, and sustained targeting of cancer cells.
In 2024, Actithera raised $75.5M in an oversubscribed Series A financing to redefine precision radioligand therapy and support the clinical development of its lead Fibroblast Activation Protein (FAP)-targeted radioligand therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Oslo, Norway
- Employees
- 30
- Open positions
- 2
- Dealroom signal
- 92.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2025 | $76M | $302M | Surveyor Capital · Sofinnova Partners · Investinor · Arkin Capital | ↗ |
Growth signals
Latest recorded traffic for Actithera is 410 monthly website visits, down 36.9% over the last three months. Actithera's team grew 900% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Sofinnova Partners
M Ventures
Hadean Ventures
4BIO Capital
Surveyor Capital
Investinor
Arkin Capital
Innovestor
Bioqube Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Actithera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Actithera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.